Viral and cellular biomarkers in the diagnosis of cervical intraepithelial neoplasia and cancer

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Tornesello, Maria Lina ^a   Buonaguro, Luigi ^a   Giorgi Rossi, Paolo ^b   Buonaguro, Franco M ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b PATHOLOGY UNIT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER; VIRUS DNA;

DNA METHYLATION; FEMALE; GENETICS; HUMAN; PAPILLOMA VIRUS; PATHOGENICITY; PATHOLOGY; REVIEW; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VIROLOGY;

CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA METHYLATION; DNA, VIRAL; FEMALE; HUMANS; PAPILLOMAVIRIDAE; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 84893749505     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/519619     Document Type: Review

References (75)

1. Ferlay J., Shin H.-R., Bray F., Forman D., Mathers C., Parkin D. M., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 2010 127 12 2893 2917 2-s2.0-78049485263 10.1002/ijc.25516
2. Arbyn M., Castellsagué X., de sanjosé S., Bruni L., Saraiya M., Bray F., Ferlay J., Worldwide burden of cervical cancer in 2008. Annals of Oncology 2011 22 12 2675 2686 2-s2.0-80053285992 10.1093/annonc/mdr015
3. Jemal A., Bray F., Forman D., O'Brien M., Ferlay J., Center M., Parkin D. M., Cancer burden in Africa and opportunities for prevention. Cancer 2012 118 18 4372 4384 2-s2.0-84855800293 10.1002/cncr.27410
4. Vaccarella S., Lortet-Tieulent J., Plummer M., Franceschi S., Bray F., Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. European Journal of Cancer 2013 49 15 3262 3273
5. Muñoz N., Bosch F. X., de Sanjosé S., Herrero R., Castellsagué X., Shah K. V., Snijders P. J. F., Meijer C. J. L. M., Epidemiologic classification of human papillomavirus types associated with cervical cancer. The New En (Pubitemid 36159887)
6. Munoz N., Castellsague X., de Gonzalez A. B., Gissmann L., Chapter 1: HPV in the etiology of human cancer. Vaccine 2006 24 supplement 3 S1 S10 (Pubitemid 44293019)
7. Bouvard V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., Benbrahim-Tallaa L., Guha N., Freeman C., Galichet L., Cogliano V., A review of human carcinogens-part B: biological agents. The Lancet Oncology 2009 10 4 321 322 2-s2.0-64849105830
8. Li N., Franceschi S., Howell-Jones R., Snijders P. J. F., Clifford G. M., Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. International Journal of Cancer 2011 128 4 927 935 2-s2.0-78650629202 10.1002/ijc.25396
9. Guan P., Clifford G. M., Franceschi S., Human papillomavirus types in glandular lesions of the cervix: a meta-analysis of published studies. International Journal of Cancer 2013 132 1 248 250
10. Meijer C. J. L. M., Helmerhorst T. J. M., Rozendaal L., van der Linden J. C., Voorhorst F. J., Walboomers J. M. M., HPV typing and testing in gynaecological pathology: has the time come? Histopathology 1998 33 1 83 86 2-s2.0-0031859213 10.1046/j.1365-2559.1998.00436.x (Pubitemid 28352577)
11. Giambi C., Donati S., Declich S., Salmaso S., degli Atti M. L. C., Alibrandi M. P., Brezzi S., Carozzi F., Collina N., Franchi D., Lattanzi A., Meda M., Minna M. C., Nannini R., Scherillo I., Bella A., Estimated acceptance of HPV vaccination among Italian women aged 18-26 years. Vaccine 2011 29 46 8373 8380 2-s2.0-80054005628 10.1016/j.vaccine.2011.08.079
12. Pyeon D., Pearce S. M., Lank S. M., Ahlquist P., Lambert P. F., Establishment of human papillomavirus infection requires cell cycle progression. PLoS Pathogens 2009 5 2 2-s2.0-61449235414 10.1371/journal.ppat.1000318 e1000318
13. Doorbar J., The papillomavirus life cycle. Journal of Clinical Virology 2005 32 supplement 1 S7 S15 (Pubitemid 40332584)
14. Onda T., Carter J. J., Koutsky L. A., Hughes J. P., Lee S.-K., Kuypers J., Kiviat N., Galloway D. A., Characterization of IgA response among women with incident HPV 16 infection. Virology 2003 312 1 213 221 2-s2.0-0041666593 10.1016/S0042-6822(03)00196-X (Pubitemid 36918473)
15. Doorbar J., Molecular biology of human papillomavirus infection and cervical cancer. Clinical Science 2006 110 5 525 541 2-s2.0-33646675570 10.1042/CS20050369 (Pubitemid 43736116)
16. Moody C. A., Laimins L. A., Human papillomavirus oncoproteins: pathways to transformation. Nature Reviews Cancer 2010 10 8 550 560 2-s2.0-77954955259 10.1038/nrc2886
17. Hopman A. H. N., Smedts F., Dignef W., Ummelen M., Sonke G., Mravunac M., Vooijs G. P., Speel E.-J. M., Ramaekers F. C. S., Transition of high-grade cervical intraepithelial neoplasia to micro-invasive carcinoma is characterized by integration of HPV 16/18 and numerical chromosome abnormalities. Journal of Pathology 2004 202 1 23 33 2-s2.0-0346025451 10.1002/path.1490 (Pubitemid 38072842)
18. Kraus I., Driesch C., Vinokurova S., Hovig E., Schneider A., Doeberitz M. V. K., Dürst M., The majority of viral-cellular fusion transcripts in cervical carcinomas cotranscribe cellular sequences of known or predicted genes. Cancer Research 2008 68 7 2514 2522 2-s2.0-42049098182 10.1158/0008-5472.CAN- 07-2776 (Pubitemid 351521828)
19. Annunziata C., Buonaguro L., Buonaguro F. M., Tornesello M. L., Characterization of the human papillomavirus (HPV) integration sites into genital cancers. Pathology and Oncology Research 2012 18 4 803 808 2-s2.0-84858732416 10.1007/s12253-012-9507-y
20. Carozzi F., Visioli C. B., Confortini M., Iossa A., Mantellini P., Burroni E., Zappa M., hr-HPV testing in the follow-up of women with cytological abnormalities and negative colposcopy. British Journal of Cancer 2013 109 7 1766 1774
21. Arbyn M., Ronco G., Anttila A., Meijer C. J., Poljak M., Ogilvie G., Koliopoulos G., Naucler P., Sankaranarayanan R., Peto J., Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012 30 supplement 5 F88 F99
22. Meijer C. J. L. M., Berkhof H., Heideman D. A. M., Hesselink A. T., Snijders P. J. F., Validation of high-risk HPV tests for primary cervical screening. Journal of Clinical Virology 2009 46 Supplement 3 S1 S4 2-s2.0-72249102138 10.1016/S1386-6532(09)00540-X
23. Dillner J., Rebolj M., Birembaut P., Petry K.-U., Szarewski A., Munk C., de Sanjose S., Naucler P., Lloveras B., Kjaer S., Cuzick J., van Ballegooijen M., Clavel C., Iftner T., Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. British Medical Journal 2008 337 a1754 2-s2.0-54549104813 10.1136/bmj.a1754
24. Ronco G., Giorgi-Rossi P., Carozzi F., Confortini M., Palma P. D., Del Mistro A., Ghiringhello B., Girlando S., Gillio-Tos A., De Marco L., Naldoni C., Pierotti P., Rizzolo R., Schincaglia P., Zorzi M., Zappa M., Segnan N., Cuzick J., Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. The Lancet Oncology 2010 11 3 249 257 2-s2.0-77649187281 10.1016/S1470-2045(09)70360-2
25. Castle P. E., Fetterman B., Poitras N., Lorey T., Shaber R., Kinney W., Relationship of atypical glandular cell cytology, age, and human papillomavirus detection to cervical and endometrial cancer risks. Obstetrics and Gynecology 2010 115 2 part 1 243 248 2-s2.0-76549106083 10.1097/AOG.0b013e3181c799a3
26. Luhn P., Wentzensen N., HPV-based Tests for Cervical Cancer Screening and Management of Cervical Disease. Current Obstetrics and Gynecology Reports 2013 2 2 76 85
27. Davies P., Kornegay J., Iftner T., Current methods of testing for human papillomavirus. Best Practice and Research Clinical Obstetrics and Gynaecology 2001 15 5 677 700 2-s2.0-0034750305 10.1053/beog.2001.0214 (Pubitemid 33026194)
28. Belinson J. L., Wu R., Belinson S. E., Qu X., Yang B., Du H., Wu R., Wang C., Zhang L., Zhou Y., Liu Y., Pretorius R. G., A population-based clinical trial comparing endocervical high-risk HPV testing using hybrid capture 2 and Cervista from the Shenccast II study. The American Journal of Clinical Pathology 2011 135 5 790 795 2-s2.0-79954997154 10.1309/AJCPKA6ATAPBZ6JQ
29. Heideman D. A. M., Hesselink A. T., Berkhof J., van Kemenade F., Melchers W. J. G., Daalmeijer N. F., Verkuijten M., Meijer C. J. L. M., Snijders P. J. F., Clinical validation of the cobas 4800 HPV test for cervical screening purposes. Journal of Clinical Microbiology 2011 49 11 3983 3985 2-s2.0-80355137211 10.1128/JCM.05552-11
30. Saslow D., Solomon D., Lawson H. W., Killackey M., Kulasingam S. L., Cain J., Garcia F. A. R., Moriarty A. T., Waxman A. G., Wilbur D. C., Wentzensen N., Downs L. S. Jr., Spitzer M., Moscicki A.-B., Franco E. L., Stoler M. H., Schiffman M., Castle P. E., Myers E. R., American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. American Journal of Clinical Pathology 2012 137 4 516 542 2-s2.0-84860564294 10.1309/AJCPTGD94EVRSJCG
31. Moyer V. A., Screening for cervical cancer: U.S. preventive services task force recommendation statement. Annals of Internal Medicine 2012 156 12 880 891
32. Meijer C. J. L. M., Berkhof J., Castle P. E., Hesselink A. T., Franco E. L., Ronco G., Arbyn M., Bosch F. X., Cuzick J., Dillner J., Heideman D. A. M., Snijders P. J. F., Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. International Journal of Cancer 2009 124 3 516 520 2-s2.0-58149292268 10.1002/ijc.24010
33. Ronco G., Confortini M., Maccallini V., Naldoni C., Segnan N., Sideri M., Zappa M., Zorzi M., Calvia M., Giorgi R. P., Health technology assessment report. Use of liquid-based cytology for cervical cancer precursors screening. Epidemiologia e Prevenzione 2012 36 5, supplement 2 e1 e33
34. Health Council of the Netherlands, Population Screening For Cervical Cancer 2011 The Hague, The Netherlands Health Council of the Netherlands
35. Arbyn M., Roelens J., Cuschieri K., Cuzick J., Szarewski A., Ratnam S., Reuschenbach M., Belinson S., Belinson J. L., Monsonego J., The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy. International Journal of Cancer 2013 132 1 101 108
36. Schweizer J., Lu P. S., Mahoney C. W., Berard-Bergery M., Ho M., Ramasamy V., Silver J. E., Bisht A., Labiad Y., Peck R. B., Lim J., Jeronimo J., Howard R., Gravitt P. E., Castle P. E., Feasibility study of a human papillomavirus E6 oncoprotein test for diagnosis of cervical precancer and cancer. Journal of Clinical Microbiology 2010 48 12 4646 4648 2-s2.0-78650061716 10.1128/JCM.01315-10
37. Cuzick J., Bergeron C., von Knebel D. M., Gravitt P., Jeronimo J., Lorincz A. T., Meijer L. M., Sankaranarayanan R., Snijders J. F., Szarewski A., New technologies and procedures for cervical cancer screening. Vaccine 2012 30 Supplement 5 F107 F116
38. Rauber D., Mehlhorn G., Fasching P. A., Beckmann M. W., Ackermann S., Prognostic significance of the detection of human papilloma virus L1 protein in smears of mild to moderate cervical intraepithelial lesions. European Journal of Obstetrics Gynecology and Reproductive Biology 2008 140 2 258 262 2-s2.0-52949098709 10.1016/j.ejogrb.2008.05.003
39. Griesser H., Sander H., Walczak C., Hilfrich R. A., HPV vaccine protein L1 predicts disease outcome of high-risk HPV+ early squamous dysplastic lesions. The American Journal of Clinical Pathology 2009 132 6 840 845 2-s2.0-72949095127 10.1309/AJCPCU0HBFFFGDTV
40. Khleif S. N., Degregori J., Yee C. L., Otterson G. A., Kaye F. J., Nevins J. R., Howley P. M., Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proceedings of the National Academy of Sciences of the United States of America 1996 93 9 4350 4354 2-s2.0-0029975913
41. Nakao Y., Yang X., Yokoyama M., Ferenczy A., Tang S.-C., Pater M. M., Pater A., Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. British Journal of Cancer 1997 75 10 1410 1416 2-s2.0-0030960749 (Pubitemid 27196859)
42. Doeberitz M. V. K., New molecular tools for efficient screening of cervical cancer. Disease Markers 2001 17 3 123 128 2-s2.0-0035663606
43. Doeberitz M. V. K., New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. European Journal of Cancer 2002 38 17 2229 2242 2-s2.0-0036850358 10.1016/S0959-8049(02) 00462-8 (Pubitemid 35346464)
44. Pannone G., Rodolico V., Santoro A., Muzio L. L., Franco R., Botti G., Aquino G., Pedicillo M. C., Cagiano S., Campisi G., Rubini C., Papagerakis S., de Rosa G., Tornesello M. L., Buonaguro F. M., Staibano S., Bufo P., Evaluation of a combined triple method to detect causative HPV in oral and oropharyngeal squamous cell carcinomas: p16 Immunohistochemistry, consensus PCR HPV-DNA, and In Situ Hybridization. Infectious Agents and Cancer 2012 7 4 2-s2.0-84857478688 10.1186/PREACCEPT-1867493228650590
45. Zhang Q., Kuhn L., Denny L. A., de Souza M., Taylor S., Wright T. C. Jr., Impact of utilizing p16INK4A immunohistochemistry on estimated performance of three cervical cancer screening tests. International Journal of Cancer 2007 120 2 351 356 2-s2.0-33845674189 10.1002/ijc.22172 (Pubitemid 44956845)
46. Carozzi F., Confortini M., Palma P. D., Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. The Lancet Oncology 2008 9 10 937 945 2-s2.0-52749088718 10.1016/S1470-2045(08)70208-0
47. Roelens J., Reuschenbach M., von Knebel D. M., Wentzensen N., Bergeron C., Arbyn M., p16INK4a immunocytochemistry versus human papillomavirus testing for triage of women with minor cytologic abnormalities: a systematic review and meta-analysis. Cancer Cytopathol 2012 120 5 294 307
48. Carozzi F., Gillio-Tos A., Confortini M., Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. The Lancet Oncology 2013 14 2 168 176
49. Reuschenbach M., Seiz M., Doeberitz C. V. K., Vinokurova S., Duwe A., Ridder R., Sartor H., Kommoss F., Schmidt D., Doeberitz M. V. K., Evaluation of cervical cone biopsies for coexpression of p16INK4a and Ki-67 in epithelial cells. International Journal of Cancer 2012 130 2 388 394 2-s2.0-83655167360 10.1002/ijc.26017
50. Schmidt D., Bergeron C., Denton K. J., Ridder R., European CINtec Cytology Study Group, p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal papanicolaou cytology study. Cancer cytopathology 2011 119 3 158 166 2-s2.0-80051606647 10.1002/cncy.20140
51. Gibbons D., Fogt F., Kasznica J., Holden J., Nikulasson S., Comparison of topoisomerase and MIB-1 expression in uterine cervical squamous lesions. Modern Pathology 1997 10 5 409 413 2-s2.0-0030611356 (Pubitemid 27244225)
52. Sahasrabuddhe V. V., Luhn P., Wentzensen N., Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts. Future Microbiology 2011 6 9 1083 1098 2-s2.0-80053544244 10.2217/fmb.11.87
53. Boucher J., Anku-Bertholet C., Temmar R., Pelmus M., Evaluation of p16INK4a, minichromosome maintenance protein 2, DNA topoisomerase II α ProEx C, and p16INK4a/ProEx C in cervical squamous intraepithelial lesions. Human Pathology 2009 40 6 904 905 2-s2.0-65149105342 10.1016/j.humpath.2009.02. 004
54. Walts A. E., Bose S., p16, Ki-67, and BD ProEx ™ C immunostaining: a practical approach for diagnosis of cervical intraepithelial neoplasia. Human Pathology 2009 40 7 957 964 2-s2.0-67349113948 10.1016/j.humpath.2008.12.005
55. Depuydt C. E., Makar A. P., Ruymbeke M. J., Benoy I. H., Vereecken A. J., Bogers J. J., BD-ProExC as adjunct molecular marker for improved detection of CIN2+ after HPV primary screening. Cancer Epidemiology Biomarkers and Prevention 2011 20 4 628 637 2-s2.0-79955783142 10.1158/1055-9965.EPI-10-0818
56. van Doorslaer K., Burk R. D., Association between hTERT activation by HPV E6 proteins and oncogenic risk. Virology 2012 433 1 216 219
57. Saha B., Chaiwun B., Tsao-Wei D. D., Groshen S. L., Naritoku W. Y., Atkinson R. D., Taylor C. R., Imam S. A., Telomerase and markers of cellular proliferation are associated with the progression of cervical intraepithelial neoplasia lesions. International Journal of Gynecological Pathology 2007 26 3 214 222 2-s2.0-34250867496 10.1097/01.pgp.0000250146.44592.d2 (Pubitemid 46986052)
58. Koskimaa H.-M., Kurvinen K., Costa S., Syrjänen K., Syrjänen S., Molecular markers implicating early malignant events in cervical carcinogenesis. Cancer Epidemiology Biomarkers and Prevention 2010 19 8 2003 2012 2-s2.0-77955455955 10.1158/1055-9965.EPI-09-0781
59. Liu H., Liu S., Wang H., Xie X., Chen X., Zhang X., Zhang Y., Genomic amplification of the human telomerase gene (hTERC) associated with human papillomavirus is related to the progression of uterine cervical dysplasia to invasive cancer. Diagnostic Pathology 2012 7 147
60. McQueen F., Duvall E., Using a quality control approach to define an 'adequately cellular' liquid-based cervical cytology specimen. Cytopathology 2006 17 4 168 174 2-s2.0-33746429487 10.1111/j.1365-2303.2006.00344.x (Pubitemid 44124654)
61. Fiorucci G., Chiantore M. V., Mangino G., Percario Z. A., Affabris E., Romeo G., Cancer regulator microRNA: potential relevance in diagnosis, prognosis and treatment of cancer. Current Medicinal Chemistry 2012 19 4 461 474 2-s2.0-84857574550 10.2174/092986712798918798
62. Gadducci A., Guerrieri M. E., Greco C., Tissue biomarkers as prognostic variables of cervical cancer. Critical Reviews in Oncology/Hematology 2013 86 2 104 129
63. Xu J., Li Y., Wang F., Wang X., Cheng B., Ye F., Xie X., Zhou C., Lu W., Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer. Oncogene 2012 32 976 987 2-s2.0-84859083416 10.1038/onc.2012.121
64. Li Y., Liu J., Yuan C., Cui B., Zou X., Qiao Y., High-risk human papillomavirus reduces the expression of microrna-218 in women with cervical intraepithelial neoplasia. Journal of International Medical Research 2010 38 5 1730 1736 2-s2.0-78449310086
65. Wang F., Li Y., Zhou J., Xu J., Peng C., Ye F., Shen Y., Lu W., Wan X., Xie X., MiR-375 is down-regulated in squamous cervical cancer and inhibits cell migration and invasion via targeting transcription factor SP1. The American Journal of Pathology 2011 179 5 2580 2588 2-s2.0-80054991467 10.1016/j.ajpath.2011.07.037
66. Bird A., DNA methylation patterns and epigenetic memory. Genes and Development 2002 16 1 6 21 2-s2.0-0036144048 10.1101/gad.947102 (Pubitemid 34049633)
67. Sharma S., Kelly T. K., Jones P. A., Epigenetics in cancer. Carcinogenesis 2009 31 1 27 36 2-s2.0-74049141478 10.1093/carcin/bgp220
68. Mirabello L., Sun C., Ghosh A., Rodriguez A. C., Schiffman M., Wentzensen N., Hildesheim A., Herrero R., Wacholder S., Lorincz A., Burk R. D., Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a costa rican population. Journal of the National Cancer Institute 2012 104 7 556 565 2-s2.0-84859486194 10.1093/jnci/djs135
69. Wentzensen N., Sun C., Ghosh A., Kinney W., Mirabello L., Wacholder S., Shaber R., LaMere B., Clarke M., Lorincz A. T., Castle P. E., Schiffman M., Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. Journal of the National Cancer Institute 2012 104 22 1738 1749
70. Sova P., Feng Q., Geiss G., Wood T., Strauss R., Rudolf V., Lieber A., Kiviat N., Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. Cancer Epidemiology Biomarkers and Prevention 2006 15 1 114 123 2-s2.0-33645461015 10.1158/1055-9965.EPI-05-0323
71. Wang S. S., Smiraglia D. J., Wu Y.-Z., Ghosh S., Rader J. S., Cho K. R., Bonfiglio T. A., Nayar R., Plass C., Sherman M. E., Identification of novel methylation markers in cervical cancer using restriction landmark genomic scanning. Cancer Research 2008 68 7 2489 2497 2-s2.0-42049110756 10.1158/0008-5472.CAN-07-3194 (Pubitemid 351521825)
72. Lai H. C., Lin Y. W., Huang T. H., Yan P., Huang R. L., Wang H. C., Liu J., Chan M. W., Chu T. Y., Sun C. A., Chang C. C., Yu M. H., Identification of novel DNA methylation markers in cervical cancer. International Journal of Cancer 2008 123 1 161 167 (Pubitemid 351705204)
73. Eads C. A., Danenberg K. D., Kawakami K., Saltz L. B., Blake C., Shibata D., Danenberg P. V., Laird P. W., MethyLight: a high-throughput assay to measure DNA methylation. Nucleic acids research 2000 28 8 E32 2-s2.0-0034654669
74. Wentzensen N., Sherman M. E., Schiffman M., Wang S. S., Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecologic Oncology 2009 112 2 293 299 2-s2.0-58249144847 10.1016/j.ygyno.2008.10.012
75. Steenbergen R. D. M., Kramer D., Braakhuis B. J. M., Stern P. L., Verheijen R. H. M., Meijer C. J. L. M., Snijder P. J. F., TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. Journal of the National Cancer Institute 2004 96 4 294 305 2-s2.0-1342291107 (Pubitemid 38256274)